Ayahuasca is a pan-Amazonian botanical hallucinogenic decoction made from a mixture of the bark of the Banisteriopsis caapi plant, containing a monoamine oxidase inhibitor, and Psychotria viridis (Rubiaceae) or Diplopterys cabrerana shrubs containing a serotonergic 2A receptor agonist, N,N-dimethyltryptamine, a powerful psychoactive substance. Ayahuasca is a traditional psychoactive sacrament...
Serotonergic hallucinogens and cannabinoids may alter the recognition of emotions in facial expressions (REFE). Cannabidiol (CBD) attenuates the psychoactive effects of the cannabinoid-1 agonist tetrahydrocannabinol. Ayahuasca is a dimethyltryptamine-containing hallucinogenic decoction. It is unknown if CBD may moderate and attenuate the effects of ayahuasca on REFE. Seventeen healthy...
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including those that are treatment-resistent. The latter half of the 20th century marked a revolution in the treatment of mental illnesses, exemplified by the introduction of selective serotonin reuptake inhibitors and other...
Ayahuasca is a South American plant hallucinogen rich in the psychedelic N,N-dimethyltryptamine and β-carbolines (mainly harmine). Preclinical and observational studies suggest that ayahuasca exerts beneficial effects in substance use disorders, but these potentials were never assessed in a clinical trial. Single-center, single-blind, feasibility, proof-of-concept study, assessing the effects...
Psychedelics are increasingly explored as tools to investigate consciousness and cognition, and as potential treatments for mood disorders. While neuroimaging has been central to characterizing their mechanisms of action, the interpretation of these studies may be confounded by the neurovascular effects elicited by these drugs. Here, we investigated the modulation of resting state neurovascular...
How do psychedelic drugs alter human brain function? Answering this question relies on our ability to understand how information is stored, transferred, and transformed across the cortex. Here, we leverage a precise mathematical framework for multivariate information decomposition to construct the first comprehensive picture of these processes across five compounds: LSD, psilocybin, ketamine,...
Abstract Ayahuasca, an amazonian brew containing the serotonergic psychedelic substance N,N-dimethyltryptamine (DMT), induces distinctive visual perceptual phenomenology, yet the neural mechanisms underlying the interplay between external visual drive and internal imagery remain unknown. Using a placebo-controlled, within-subject fMRI design, the present study investigated the impact of...
Consciousness eludes unified scientific explanation, entwining subjective experience with observable brain processes. Neural thermodynamics (NT) introduces a quantitative framework to bridge this divide, modeling consciousness through neural temperature (Tneural), energy (ΔE), and entropy (ΔS). Grounded in statistical mechanics and the Free Energy Principle, NT merges neuroscience and physics...
Minimal Phenomenal Experiences (MPEs) present a paradox for theories of consciousness.Defined by phenomenological simplicity, they are nonetheless accompanied by unexpectedly highneural signal diversity. Traditionally, entropy has been interpreted as a marker ofphenomenological richness, exemplified by psychedelic states. Yet MPEs such as advancedabsorptive meditation (jhāna) or 5-MeO-DMT...
Patients undergoing ketamine-or psychedelic-assisted therapy for cancer-related distress, treatment-resistant depression, or end-of-life existential fear frequently report experiences resembling death or near-death: a sense of leaving the body, encountering something transcendent, or having died and returned. This synthesis reviews peer-reviewed evidence on how often this occurs, why it may...